Chelating ligands with high affinity to PSMA have been developed for imaging (68Ga-HBED-PSMA) and RLT (177Lu-PSMA-617) in order to translate this concept into prostate cancer patients [5, 11]. This evidence concerns the gene FOLH1 and prostate carcinoma.